Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of A431 cells expressing control or ARID1A-targeting shRNAs

ABSTRACT: RNA-seq of A431 cells expressing control or ARID1A-targeting shRNAs

PROVIDER: PRJNA542696 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9905110_1.fastq.gz	Fastqsanger.gz
	SRR9905110_2.fastq.gz	Fastqsanger.gz
	SRR9905111_1.fastq.gz	Fastqsanger.gz
	SRR9905111_2.fastq.gz	Fastqsanger.gz
	SRR9905112_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

RNA-seq of A431 cells expressing control or ARID1A-targeting shRNAs

Project description:We examined gene expression level in A431 cells expressing control or ARID1A-targeting shRNAs to study the mechanism underlying the tumor suppressive effect of ARID1A.

2019-11-30 | GSE131132 | GEO

RNA-seq of KYSE410 cells expressing control, USP11 or ARID1A-targeting shRNAs

Project description:We examined gene expression level in KYSE410 cells expressing control, USP11 or ARID1A-targeting shRNAs to study the mechanism underlying the tumor suppressive effect of ARID1A and USP11.

2019-11-30 | GSE132359 | GEO

RNA-seq of KYSE410 cells expressing control, USP11 or ARID1A-targeting shRNAs

Project description:RNA-seq of KYSE410 cells expressing control, USP11 or ARID1A-targeting shRNAs

| PRJNA547719 | ENA

Poly(A)+ RNA-seq from H226 cells expressing doxycycline-inducible Control (non-targeting) and p63-targeting shRNAs

Project description:Poly(A)+ RNA-seq from H226 cells expressing doxycycline-inducible Control (non-targeting) and p63-targeting shRNAs

| PRJNA437576 | ENA

sgRNA cassette sequencing and RNA-seq from H226 cells expressing doxycycline-inducible Control (non-targeting) and p63-targeting shRNAs

Project description:sgRNA cassette sequencing and RNA-seq from H226 cells expressing doxycycline-inducible Control (non-targeting) and p63-targeting shRNAs

| PRJNA437621 | ENA

human epidermoid carcinoma cell: Control (A431-P cells) vs. highly invasive subline (A431-III cells)

Project description:Transcriptional profiling of human epidermoid carcinoma cell comparing control A431-P cells with highly invasive subline A431-III cells

2013-06-18 | GSE47996 | GEO

human epidermoid carcinoma cell: Control (A431-P cells) vs. highly invasive subline (A431-III cells)

Project description:Transcriptional profiling of human epidermoid carcinoma cell comparing control A431-P cells with highly invasive subline A431-III cells No treatmentt, A431-P cells vs. A431-III cells. A431-P cells are used as a reference to invstigate A431-III cells.

2013-06-18 | E-GEOD-47996 | biostudies-arrayexpress

LNCaP prostate cancer cells stably transfected with shRNAs targeting ADRB2

Project description:Gene expression profiling of prostate adenocarcinoma LNCaP cells stably transfected with shRNAs targeting ADRB2 (shADRB2-2 and shADRB2-3) or control shRNA (shCtrl) incubated in 10% FCS.

2019-04-25 | GSE130204 | GEO

Targeting EZH2 methyltransferase activity in ARID1A mutated cells as a synthetic lethal therapeutic strategy

Project description:ARID1A, an epigentic modifier, is often mutated in ovarian clear cell carcinoma (OCCC). In addition, EZH2 is frequently upregulated in OCCC. Inhibtion of EZH2 with an inhibitor (GSK126) selectively inhibits ARID1A-mutated cells. This study was designed to understand changes in gene expression profiles following EZH2 inhibition or ARID1A restoration. Chromatin remodelers such as ARID1A are frequently mutated in a broad array of cancers. However, targeted cancer therapy based on ARID1A mutation status has not been described. Intriguingly, ARID1A mutated cancers typically lack genomic instability, suggesting significant involvement of epigenetic mechanisms. Here we show that inhibition of the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A mutated cells. Remarkably, ARID1A mutation status correlated with response to EZH2 inhibitor. Genome-wide profiling revealed antagonistic roles of ARID1A and EZH2 in gene regulation. Further, we identified PIK3IP1 as a direct ARID1A/EZH2 target gene whose upregulation contributes to the observed synthetic lethality in the EZH2 inhibitor treated ARID1A mutated cells. Significantly, EZH2 inhibitor caused the regression of established ARID1A mutated tumors in vivo. Together, this data demonstrate a synthetic lethality between ARID1A mutation and EZH2 inhibition. They indicate that pharmacological inhibition of EZH2 represents a novel treatment strategy for ARID1A mutated cancers.

2015-01-20 | E-GEOD-54979 | biostudies-arrayexpress

Expression data to parental A431 VS CD109 KO A431

Project description:Expression data to parental A431 VS CD109 KO A431

| PRJNA482298 | ENA